Cue Biopharma, Inc.: Bleichroeder LP amends Schedule 13G stake filing
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 10 November 2026, by SEC EDGAR SCHEDULE 13G
25
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Bleichroeder LP amended its Schedule 13G filing on Cue Biopharma, Inc., updating its beneficial ownership stake with the SEC under accession number 0001420506-26-002561. The filing was disclosed via SEC EDGAR. The amendment signals a change in the institutional investor's position in the clinical-stage biopharmaceutical company. Investors should watch for further 13G or 13D filings to gauge whether Bleichroeder's stake continues to shift.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Bleichroeder LP, Cue Biopharma, Inc.